MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-53M

42M

Müük

-65M

665M

P/E

Sektori keskmine

40.789

39.564

Aktsiakasum

1.01

Dividenditootlus

0.29

Kasumimarginaal

6.268

Töötajad

11,000

EBITDA

-50M

173M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+16.3% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.29%

2.40%

Järgmine tulemuste avaldamine

28. juuli 2025

Järgmine dividendimakse kuupäev

8. aug 2025

Järgmine aktsia dividendi kuupäev (ex-date)

18. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-2.4B

12B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

26%

74%

54 / 376 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuli 2025, 15:46 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250 Million Private Placement

9. juuli 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 20:26 UTC

Tulu

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9. juuli 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9. juuli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9. juuli 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9. juuli 2025, 17:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9. juuli 2025, 16:14 UTC

Omandamised, ülevõtmised, äriostud

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9. juuli 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9. juuli 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9. juuli 2025, 15:31 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250M Private Placement

9. juuli 2025, 15:31 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9. juuli 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9. juuli 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9. juuli 2025, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9. juuli 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9. juuli 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

16.3% tõus

12 kuu keskmine prognoos

Keskmine 117.07 USD  16.3%

Kõrge 135 USD

Madal 100 USD

Põhineb 14 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

14 ratings

9

Osta

5

Hoia

0

Müü

Sentiment

By Acuity

54 / 376 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.